Role of heat treatment in childhood cancers: Distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy

Debes, Anette; Willers, Reinhart; Göbel, U.; Wessalowski, Rüdiger

doi:10.1002/pbc.20266

Cited by 14 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, hyperthermia has also been found to be effective in enhancing the anticancer activity of chemotherapeutic drugs 321 . This is supported by a study carried out by Debes et al 322 which showed that hyperthermia synergistically enhances the cytotoxicity of an alkylating agent, cisplatin, in NB cells. Targeted image‐guided drug delivery (IGDD) is a technique that has been developed to improve drug deposition in a variety of diseases, including cancer 323 .…”

Section: General Discussion and Future Research Directionsmentioning

confidence: 55%

Molecular targeting therapies for neuroblastoma: Progress and challenges

Zafar

Wang

Liu

et al. 2020

Medicinal Research Reviews

198

139

View full text Add to dashboard Cite

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is the most common pediatric solid tumor, and accounts for ~15% of childhood cancer‐related mortality. Neuroblastomas exhibit genetic, morphological and clinical heterogeneity, which limits the efficacy of existing treatment modalities. Gaining detailed knowledge of the molecular signatures and genetic variations involved in the pathogenesis of neuroblastoma is necessary to develop safer and more effective treatments for this devastating disease. Recent studies with advanced high‐throughput “omics” techniques have revealed numerous genetic/genomic alterations and dysfunctional pathways that drive the onset, growth, progression, and resistance of neuroblastoma to therapy. A variety of molecular signatures are being evaluated to better understand the disease, with many of them being used as targets to develop new treatments for neuroblastoma patients. In this review, we have summarized the contemporary understanding of the molecular pathways and genetic aberrations, such as those in MYCN, BIRC5, PHOX2B, and LIN28B, involved in the pathogenesis of neuroblastoma, and provide a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators. We also give insights on the use of combination therapies involving novel agents that target various pathways. Further, we discuss the future directions that would help identify novel targets and therapeutics and improve the currently available therapies, enhancing the treatment outcomes and survival of patients with neuroblastoma.

show abstract

Section: General Discussion and Future Research Directionsmentioning

confidence: 55%

Molecular targeting therapies for neuroblastoma: Progress and challenges

Zafar

Wang

Liu

et al. 2020

Medicinal Research Reviews

198

139

View full text Add to dashboard Cite

show abstract

“…The cellular responses to HT are different and depend mainly on temperature and protocols employed (Table 1). Therefore, it is mandatory to investigate and know the correct temperature to be used in different tumors, because just a degree of difference might change strongly the effect of treatment [105,106]. One of the mechanisms by which HT causes cell death involves the heat shock proteins (HSPs) pathway and the different expression level of HSPs in different tumor cells seems to be one of the major reasons for the variances in thermo-sensitivity [33,34,35].…”

Section: Application Of Biophysical Therapies In Osteosarcomamentioning

confidence: 99%

“…Debes et al demonstrated that HT at 43 °C, but not at 42 °C, influenced differently OS cell viability, depending on OS aggressiveness, affecting strongly MG-63 and KHOS cell line and only weakly U-2 OS and Saos2 cell line [105]. Moreover they showed also that HT was able to enhance the cytotoxic effect of cisplatin, affecting cell viability at both temperatures, with a stronger effect at 43 °C [105]. Other studies showed that HT conditions sensitize OS cell line to paclitaxel and cisplatin or etoposide combinations by upregulating Fas expression [110,111].…”

Section: Application Of Biophysical Therapies In Osteosarcomamentioning

confidence: 99%

Adjuvant Biophysical Therapies in Osteosarcoma

Carina

Costa

Sartori

et al. 2019

Cancers

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary bone sarcoma, manifesting as osteogenesis by malignant cells. Nowadays, patients’ quality of life has been improved, however continuing high rates of limb amputation, pulmonary metastasis and drug toxicity, remain unresolved issues. Thus, effective osteosarcoma therapies are still required. Recently, the potentialities of biophysical treatments in osteosarcoma have been evaluated and seem to offer a promising future, thanks in this field as they are less invasive. Several approaches have been investigated such as hyperthermia (HT), high intensity focused ultrasound (HIFU), low intensity pulsed ultrasound (LIPUS) and sono- and photodynamic therapies (SDT, PDT). This review aims to summarize in vitro and in vivo studies and clinical trials employing biophysical stimuli in osteosarcoma treatment. The findings underscore how the technological development of biophysical therapies might represent an adjuvant role and, in some cases, alternative role to the surgery, radio and chemotherapy treatment of OS. Among them, the most promising are HIFU and HT, which are already employed in OS patient treatment, while LIPUS/SDT and PDT seem to be particularly interesting for their low toxicity.

show abstract